Figure 2From: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer Relationship between miRNA-126 and response. (A) Distribution of miRNA-126 expression levels according to response or non-response to first line XELOX in patients with mCRC, black bars represent the medians, n = 83. The difference between the medians in the two groups was significant, p = 0.000005. (B) Illustration of the same distribution divided into the four response groups (PD; progressive disease, SD; stable disease, PR; partial response and CR; complete response). A significant difference between the median miRNA-126 expression levels in the patients achieving SD compared to PR was observed, p = 0.001. The miRNA-126 expression levels from five patients (outliers, levels ranging from 16775-40284) are not shown in the figures for graphical reasons only, but were included in the statistics. Two of these patients achieved PR and the remaining three CR.Back to article page